The "Oligonucleotide Synthesis Market: Industry Trends and Global Forecasts, Till 2035 - Application Area, Type of Product Synthesized, Type of Oligonucleotide Synthesized, Scale of Operation, Therapeutic Area, End-Users, Company Size and Key Geographical Regions" report has been added to ResearchAndMarkets.com's offering.
The global oligonucleotide synthesis market is estimated to be worth $ 4.8 billion in 2024 and is expected to grow at compounded annual growth rate (CAGR) of 9.9% during the forecast period 2024-2035.
The new research study consists of industry trends, detailed oligonucleotide synthesis market analysis, key market insights, market impact analysis, and oligonucleotide synthesis market forecast and opportunity analysis. The growth in the opportunity for contract manufacturers over the next decade is likely to be the result of the anticipated rise in the demand for oligonucleotide therapeutics.
Oligonucleotides or oligos are short single stranded fragments of DNA or RNA molecules. These typically consist of 10-50 nucleotide chains with each chain made up of phosphate group, a sugar molecule (deoxyribose in DNA and ribose in RNA), and a nitrogenous base. The nitrogenous base can be adenine (A), cytosine (C), guanidine (G) and thymine (T) in DNA, or adenine (A), cytosine (C), guanidine (G) and uracil (U) in RNA. These molecules play a crucial role in genetic testing, molecular testing and various other analytical testing procedures, such as artificial gene synthesis and polymerase chain reactions.
With the approval of the first antisense oligonucleotide drug, Vitravene, the applications of oligonucleotides in research and diagnostics, in addition to therapeutics, have significantly increased. Several preclinical and clinical studies have demonstrated the potential of oligonucleotides as a safe and effective treatment modality; these molecules possess unique characteristics, such as high target specificity and superior pharmacokinetic profile.
Presently, over 15 oligonucleotide-based therapies have been approved globally. Notable examples of recently approved products include (in reverse chronological order of year of approval) Amvuttra (2022), AMONDYS 45 (2021), Leqvio (2021) and Oxlumo (2020). Additionally, close to 300 clinical studies are currently evaluating around 80 oligonucleotides for over 102 different indications across 14 therapeutic areas, targeting 66 different genes.
Pipeline Analysis: Competitive Landscape of Oligonucleotide Synthesis Providers
The oligonucleotide synthesis market landscape features 110+ very large, large, mid-sized and small oligonucleotide synthesis providers offering custom oligonucleotide synthesis, oligonucleotide modification and oligonucleotide purification services, which are intended for research, diagnostic and therapeutic applications. Further, the most commonly adopted modification techniques for oligonucleotides include labeling modifications, backbone modifications and modified bases.
It is worth highlighting that modified bases are locked nucleic acids that can be incorporated into DNA or RNA at multiple sites during synthesis in order to enhance the therapeutic effect of the product. Examples of companies offering modified bases include (arranged in alphabetical order) Eurofins Genomics, Integrated DNA Technologies, LGC Biosearch Technologies and ThermoFisher Scientific. Furthermore, HPLC is the most commonly used technique for oligonucleotides purification, followed by polyacrylamide gel electrophoresis. This can be attributed to the fact that these techniques help to obtain highly pure and premium quality oligonucleotides. In addition, various high throughput RNA/DNA synthesizers are being launched with advanced purification technology to improve yield.
Market Trend Analysis: Partnerships and Collaborations have Fueled the Oligonucleotide Synthesis Market Growth
In recent years, several partnerships have been established by industry stakeholders, in order to consolidate their presence in this field, and enhance their capabilities and product portfolio to meet the growing demand for oligonucleotide-based therapeutics. It is worth highlighting that over 30% of these partnerships have been inked in the past two years. Interestingly, most of the agreements signed between the stakeholders were acquisition and manufacturing agreements. For instance, in August 2023, EUROAPI acquired BianoGMP to strengthen its CDMO expertise in the domain.
Clinical Trial Analysis: Close to 300 Trials are Evaluating Oligonucleotides to Treat Myriad of Disease Indications
Close to 300 clinical trials have been registered across different geographical regions to evaluate various oligonucleotides. Majority (>50%) of these trials were registered in North America. Further, the maximum number of patients (19,590) have been enrolled in clinical trials conducted in Europe, which account for 26% of the overall enrollment. It is worth mentioning that Ionis Pharmaceuticals is conducting the maximum number of trials in this industry for various target indications, including atherosclerosis, Crohn's disease, elevated triglycerides, familial chylomicronemia syndrome, hATTR amyloidosis rheumatoid arthritis, transthyretin-mediated amyloid cardiomyopathy and type 2 diabetes mellitus.
Regional Analysis: North America Emerges as the Hub of Oligonucleotide Synthesis Market; Asia-Pacific to be the Fastest Growing Market
Majority of the oligonucleotide synthesis providers are headquartered in North America, followed by companies based in Europe. Currently, North America and Europe capture around 75% of the market share of the global oligonucleotide synthesis market. In recent years, demand for oligonucleotide-based products in the North America region has witnessed a significant increase owing to increasing R&D investments and number of clinical studies pertaining to the development of oligonucleotides / oligonucleotide-based products. It is worth highlighting that, in the coming years, the market in Asia-Pacific is likely to grow at a higher owing to the lower manufacturing costs, cheap and skilled labor and supportive regulatory landscapes in this region.
The opinions and insights presented in this study were Influenced by discussions conducted with multiple stakeholders in the oligonucleotide synthesis market. In addition, the research report features detailed transcripts of interviews held with the following industry stakeholders (arranged on the basis of designation):
- Founder and Managing Director, Small Company, Germany
- Co-Founder and Managing Director, Small Company, India
- Chief Scientific Officer and Managing Director, Small Company, Germany
- Managing Director, Mid-sized Company, Germany
- Business Officer, Mid-sized Company, China
- Chem Lab Manager, Small Company, US
- Global Corporate Sales and Business Development, Small Company, Germany
Oligonucleotide Synthesis Market Share Insights
- Historical Trend: 2018-2022
- Base Year: 2023
- Forecast Period: 2024-2035
- Market Size in 2024: $4.8 Billion
- CAGR: 9.9%
- Application Area
- Research and Diagnostics
- Therapeutics
-
Type of Product Synthesized
- Active Pharmaceutical Ingredients
- Finished Dosage Forms
-
Type of Oligonucletide Synthesized
- Antisense
- DNA
- siRNA
- Other Oligonucleotides
-
Scale of Operation
- Clinical
- Commercial
-
Therapeutic Area
- Cardiovascular Disorders
- Genetic Disorders
- Liver Disorders
- Rare Diseases
- Other Disorders
-
End-users
- Pharmaceutical/Biopharmaceutical Companies
- Academic And Research Institutes
- Hospitals
-
Company Size
- Small
- Mid-sized
- Large and Very Large
-
Key Geographical Regions
- North America
- Europe
- Asia-Pacific
- Rest of the World
-
Key Companies Profiled
- Agilent Technologies
- Ajinomoto Bio-Pharma Services
- CordenPharma
- Creative Biolabs
- Ella Biotech
- Eurofins Genomics
- Future synthesis
- Integrated DNA Technologies
- Kaneka Eurogentec
- LGC Biosearch Technologies
- Merck
- Microsynth
- Nitto Avecia
- Ribo Biotechnology
- STA Pharmaceutical / Wuxi STA
- Sumitomo Chemical
- Thermo Fisher Scientific
- TriLink Biotechnologies
- (Full list of more than 100 companies captured is available in the report)
- PowerPoint Presentation (Complimentary)
- Customization Scope: 15% Free Customization
-
Excel Data Packs (Complimentary)
- Market Landscape
- Company Competitiveness Analysis
- Clinical Trial Analysis
- Big Pharma Initiatives
- Partnerships and Collaborations
- Recent Expansions
- Capacity Analysis
- Demand Analysis
- Market Forecast and Opportunity Analysis
Key Topics Covered:
1. Preface
2. Research Methodology
3. Economic And Other Project Specific Considerations
4. Executive Summary
5. Introduction
6. Market Landscape
7. Company Competitiveness Analysis
8. Company Profiles
9. Make Versus Buy Decision Making Framework
10. Clinical Trial Analysis
11. Partnerships And Collaborations
12. Recent Expansions
13. Big Pharma Initiatives
14. Capacity Analysis
15. Demand Analysis
16. Market Impact Analysis
17. Global Oligonucleotide Synthesis Market
18. Oligonucleotide Synthesis Market, By Application Area
19. Oligonucleotide Synthesis Market, By Type Of Product Synthesized
20. Oligonucleotide Synthesis Market, By Type Of Oligonucleotide Synthesized
21. Oligonucleotide Synthesis Market, By Scale Of Operation
22. Oligonucleotide Synthesis Market, By Therapeutic Area
23. Oligonucleotide Synthesis Market, By End-Users
24. Oligonucleotide Synthesis Market, By Company Size
25. Oligonucleotide Synthesis Market: Distribution By Key Geographical Regions
26. Executive Insights
27. Concluding Remarks
For more information about this report visit https://www.researchandmarkets.com/r/z0ywsy
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240719482744/en/
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
